1. Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. The New England journal of medicine. 2016; 375:2550-2560.
  2. Cavalli FMG; Remke M; Rampasek L; Peacock J; Shih DJH; Luu B; Garzia L; Torchia J; Nor C; Morrissy AS. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31:737-754.e6.
  3. Torchia J; Golbourn B; Feng S; Ho KC; Sin-Chan P; Vasiljevic A; Norman JD; Guilhamon P; Garzia L; Agamez NR. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016; 30:891-908.
  4. Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016; 30:737-749.
  5. von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2016; 34:4381-4389.
  6. Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DTW; Luu B; Cavalli FMG; Aldape K. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology. 2016; 34:2468-2477.
  7. Tiao G; Geller J; Timchenko NA. Generation of Pediatric Liver Cancer Patient-Derived Xenograft Platforms for Pediatric Liver Cancer: A Critical Stage in the Development of Anticancer Treatments. Hepatology. 2016; 64:1017-1019.
  8. Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research. 2017; 23:2433-2441.
  9. Ooms AHAG; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clinical Cancer Research. 2016; 22:5582-5591.
  10. Fernandez CV; Perlman EJ; Mullen EA; Chi Y-Y; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor A Report From Children's Oncology Group AREN0532. Annals of Surgery. 2017; 265:835-840.
  11. Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. Cancer Research. 2016; 76:7219-7230.
  12. Goyama S; Shrestha M; Schibler J; Rosenfeldt L; Miller W; O'Brien E; Mizukawa B; Kitamura T; Palumbo JS; Mulloy JC. Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. Oncogene: Including Oncogene Reviews. 2017; 36:2589-2598.
  13. Milewski D; Pradhan A; Wang X; Cai Y; Le T; Turpin B; Kalinichenko VV; Kalin TV. FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor. Oncogene: Including Oncogene Reviews. 2017; 36:850-862.
  14. Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. PLoS genetics. 2016; 12:e1006501.
  15. Fouladi M; Pfister SM. MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?. Neuro-Oncology. 2017; 19:741-743.
  16. Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ. Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncology. 2016; 18:1319-1325.
  17. Huibregtse KE; Vo KT; DuBois SG; Fetzko S; Neuhaus J; Batra V; Maris JM; Weiss B; Marachelian A; Yanik GA. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with I-131-metaiodobenzylguanidine. European Journal of Cancer. 2016; 66:144-152.
  18. Wagner LM; Kremer N; Gelfand MJ; Sharp SE; Turpin BK; Nagarajan R; Tiao GM; Pressey JG; Yin J; Dasgupta R. Detection of Lymph Node Metastases in Pediatric and Adolescent/Young Adult Sarcoma: Sentinel Lymph Node Biopsy Versus Fludeoxyglucose Positron Emission Tomography Imaging-A Prospective Trial. Cancer. 2017; 123:155-160.
  19. Smith EA; Gole B; Willis NA; Soria R; Starnes LM; Krumpelbeck EF; Jegga AG; Ali AM; Guo H; Meetei AR. DEK is required for homologous recombination repair of DNA breaks. Scientific Reports. 2017; 7:44662.
  20. Smith EA; Kumar B; Komurov K; Smith SM; Brown NV; Zhao S; Kumar P; Teknos TN; Wells SI. DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma. Oncotarget. 2017; 8:23414-23426.
  21. Koncar RF; Chu Z; Romick-Rosendale LE; Wells SI; Chan TA; Qi X; Bahassi EM. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. Oncotarget. 2017; 8:15827-15837.
  22. Dandoy CE; Hausfeld J; Flesch L; Hawkins D; Demmel K; Best D; Osterkamp E; Bracke T; Nagarajan R; Jodele S. Rapid cycle development of a multifactorial intervention achieved sustained reductions in central line-associated bloodstream infections in haematology oncology units at a children's hospital: a time series analysis. BMJ Quality and Safety. 2016; 25:633-643.
  23. Mizuno T; Fukuda T; Christians U; Perentesis JP; Fouladi M; Vinks AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. British Journal of Clinical Pharmacology. 2017; 83:1097-1107.
  24. Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis. PloS one. 2017; 12:e0177952.
  25. Bahar M; Hashem H; Tekautz T; Worley S; Tang A; de Blank P; Wolff J. Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience. Journal of Neuro-Oncology. 2017; 132:427-432.